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Ephedrine-type alkaloids (ETA) are major active ingredients of Ephedra, a 
traditional Chinese medicinal herb used to treat asthma and nasal congestion. Until 
recently, large amounts of Ephedra were used in dietary supplements for weight loss 
and athletic performance enhancement. However, indiscriminate consumption of 
ETA-containing products has resulted in more than 1,000 reported cases of adverse 
effects. The objective of this study is to evaluate bioactivity of ETA. The toxicities of 
(-)-ephedrine and (+)-pseudoephedrine were measured using MTT assay on human 
neuroblastoma (SH-SY5Y) and rat myoblastoma (H9c2 (2-1)), while the stress 
responses of a panel of biosensing bioluminescent Escherichia coli strains were 
analyzed. SH-SY5Y showed similar sensitivity to (-)-ephedrine and (+)-
pseudoephedrine, while H9c2 (2-1) could differentiate the cytotoxicity of (-)-
ephedrine and (+)-pseudoephedrine. The biosensing of the E. coli strains was highly 
sensitive to the toxicity of ETA and could yield instantaneous response. The RLU 
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CHAPTER 1: INTRODUCTION 
 
More than half of the U.S. adult population uses dietary supplement products, 
and consumers spend approximately $12 billion annually on dietary supplements, 
according to the 1998 Nutrition Business Journal Annual Industry Overview 
(Nutrition Business Journal, 1998). In the last decade, large amounts of ephedrine-
type alkaloids (ETA) were used in numerous dietary supplements formulated for 
weight reduction and athletic performance enhancement (Dulloo and Stock, 1993). 
However, indiscriminate consumption of ETA-containing products has resulted in 
more than 1,000 reported cases of poisoning and other serious effects since 1993, 
some of which were fatal (FDA, 2000). 
Used in the Far East to treat asthma, nose and lung congestion, and fever with 
anhidrosis (Lee et al., 2000), Ephedra (ma huang), a traditional Chinese medicine 
(TCM) derived from Ephedra sinica Stapf and other Ephedra species, is the major 
sources of ETA. To date, the quality of Ephedra has been determined by the contents 
of total ETA, with higher contents indicating better quality. However, although 
individual ETA has similar pharmacological activity, they vary significantly in 
potency (Cetaruk and Aaron, 1994). Both the contents and the profile of ETA in 
Ephedra vary with plant species and varieties (Cui et al., 1991), plant parts (Liu et al., 
1993), seasons of harvest (Kasahara et al., 1986), and geographical origins (Zhang et 
al., 1989). In addition to ETA, Ephedra also contains other phytoconstituents, which 
may modify its pharmacological and toxicological activities. Therefore, the toxicity 




bioassay is needed to determine the total toxicity of Ephedra due to the combined 
effect of the alkaloids and other constituents. 
The overall objective of this study is to evaluate bioactivity of ephedrine-type 
alkaloids by measuring its cytotoxicity against selected cell lines and analyzing the 
stress responses of a panel of six genetically engineered biosensing strains capable of 
producing real-time responses to environmental stresses that cause specific cell 
damage. To accomplish these objectives, the study will be divided into two parts. The 
first part involves detecting and profiling the cytotoxicity of ephedrine-type alkaloids 
against the two cell lines —human neuroblastoma and rat myoblastoma—using MTT 
cell proliferation assay techniques. The second part involves a panel of six strains of 















Ephedra, also known as ma huang, belongs to the family Ephedraceae that is 
an evolutionarily primitive plant family (Blumenthal and King, 1995). Ephedra 
species favor dry, sandy or rocky environments, and are found in the temperate and 
subtropical regions of China, Mongolia, India, parts of the Mediterranean and 
Afghanistan as well as regions of North and Central America (Blumenthal and King, 
1995). Although the genus Ephedra consists of more than 50 species (Schaneberg et 
al., 2003), primary species of Ephedra are represented by Ephedra sinica, E. major 
Host, E. gerardiana Wall, E. intermedia Schrenk & Meyer, and E. equisetina Bunge 
(Morton, 1977). 
Ephedra species are short, evergreen and almost leafless shrubs that grow 
about 60 to 90 cm high (23.5 to 35.5 inches high). The stems are green in color, 
slender, erect or reclining, small ribbed and channeled, about 1.5 mm in diameter and 
usually terminating in a sharp point. Nodes are 4 to 6 cm apart, and small triangular 
leaves appear at the stem nodes (Blumenthal and King, 1995). The nodes are 
characteristically reddish brown. The stems usually branch form the base (Blumenthal 
and King, 1995).  They bear minute, yellow-green flowers and fruits, and emit a 






The major active ingredients of Ephedra are alkaloids that constitute 0.5 to 2.5 
percent of the total mass, and are referred to as ephedrine-type alkaloids (Blumenthal 
and King, 1995).  The six optically active alkaloids that have been isolated from 
Ephedra species are (-)-ephedrine, (+)-pseudoephedrine, (-)-N-methylephedrine, (+)-
N-methylpseudoephedrine, (-)-norephedrine, (+)-norpseudoephedrine. Usually, (-)-
ephedrine is the major isomer that comprises 30 to 90 percent of total alkaloid 
fraction accompanied by (+)-pseudoephedrine, with trace amount of other ephedrine-
type alkaloids (Blumenthal and King, 1995). The total content of ephedrine-type 
alkaloids depends on the species of Ephedra, time of year of harvest, weather 
conditions, and altitude where the plant grows (Blumenthal and King, 1995), and can 
exceed 2% (Bruneton, 1995). This variation according to environmental conditions 
explains why some Ephedra containing dietary supplements of the same brand often 
show alkaloid content markedly differing from label claims and also variation among 
lots when analyzed chemically (Gurley et. al., 2000). 
Preparation of ephedrine-type alkaloids from crude plant material involves an 
acid/base extraction procedure (Reti, 1953). In addition to the extraction from plants, 
ephedrine-type alkaloids can also be chemically synthesized, and most of the 
ephedrine and pseudoephedrine used in western medicine has been manufactured 
synthetically. However, these synthetic ephedrine-type alkaloids differ from the 
natural forms in that they are racemic, i.e., optically inactive, because they are made 




In addition to the ephedrine-type alkaloids, other alkaloids and amino 
compounds have been isolated from different species of Ephedra. The macrocyclic 
spermine alkaloids, Ephedradines A-D, kynurenic acid derivatives, cyclopolyglycine, 
methanoproline amino acids, flavones, flavanols, tannins, carboxylic acids, volatile 









   
 
Figure 2-1. Chemical structures of (-)-ephedrine and (+)-pseudoephedrine 
 (adapted from Abourashed et al., 2003) 
 
2.1.3. Pharmacology 
Ephedrine is a sympathomimetic substance that stimulates both - and -
adrenergic receptors (Abourashed et al., 2003).  Stimulation of 1-adrenergic 
receptors produces contraction of vascular smooth muscle, increased contractile force 













relaxation of intestinal smooth muscle. Stimulation of 2-adrenergic receptors 
decreases insulin secretion, platelet aggregation and the release of norepinephrine 
from the nerve terminals, and causes contraction of vascular smooth muscle. 
Stimulation of 1-adrenergic receptors increases force and rate of contraction of the 
heart, increased velocity of conduction through the atrioventricular node, and 
increased rennin secretion. When used in therapeutic doses, stimulation of 2-
adrenergic receptors causes relaxation of the smooth muscle of the blood vessels and 
bronchi (Mack, 1997). Stimulation of -adrenergic receptors including 3-subtype 
involve in lypolysis and non-shivering thermogenesis (Abourashed et al., 2003). In 
addition to its direct effects, ephedrine also displays indirect sympathetic activation 
releasing norepinephrine from sympathetic neurons (Abourashed et al., 2003). 
Ephedrine also has central nervous system (CNS) stimulant effects similar to those of 
amphetamines, but less pronounced (McEvoy, 2000).  
 
2.2. Use of Ephedra 
2.2.1. Traditional Use 
The Ephedra species have been dispensed in traditional Chinese medicines 
(TCM) for at least 5,000 years (Morton, 1977). In traditional Chinese medicines, 
dried stems of Ephedra species are used to alleviate symptoms caused by common 
cold, influenza, asthma, bronchitis, nasal congestion and hay fever. They were also 
used for a treatment of arthritis, fever, hives, lack of perspiration, headache, aching 
joints and bones, wheezing, and low blood pressure (Leung and Foster, 1996). The 




sinica, E. equisetina and E. intermedia), which are usually boiled in water and 
administered as a hot tea. In contrast to the diaphoretic uses properties of ma-huang 
(stem part), the root and rhizome of Ephedra species, called mahuanggen, have 
antiperspirant property and are employed to treat spontaneous and night sweating 
(Leung, 1990).  
In Western medicine, ephedrine is used for the treatment of nasal congestion 
due to hay fever, allergic rhinitis, asthma, and common cold (WHO, 1999). Also, 
ephedrine salts are prescribed in the form of nasal sprays to relieve congestion and 
swelling. When injected subcutaneously, ephedrine prevents hypotension during 
anesthesia. Orally, it has been used in treating certain forms of epilepsy, nocturnal 
enuresis, myasthenia gravis, and urticaria accompanying angioneurotic edema. 
Pseudoephedrine, taken orally, is an effective nasal decongestant (Morton, 1977).  
 
2.2.2. As Dietary Supplements 
Approximately a decade ago, a new usage of Ephedra different from tradition 
directions had been widespread in the United States. Focusing on the thermogenic 
and lypolytic effects of Ephedra, dietary supplements containing Ephedra extracts 
have been commercially promoted and used as a mean of weight reduction and 
energy enhancement (Josefson, 1995). These dietary supplements are often combined 
with other botanical ingredients such as St John's wort and stimulants including 
guarana (caffeine source), carnitine, creatine (CANTOX, 2000).  
However, since 1994, there has been increasing number of reports of adverse 




Drug Administration (FDA).  Reported reactions varied from the milder adverse 
effects such as nervousness, dizziness, tremor, headache, and gastrointestinal distress 
to chest pain, myocardial infarction, hepatitis, stroke and death. Of 140 reports 
submitted to the FDA between June 1997 and March 1999, 47% involved 
cardiovascular symptoms and 18% neurological symptoms. Severe hypertension was 
the single most frequent adverse effect followed by tachycardia, myocardial 
infarction, stroke, seizure. Ten events resulted in death and 13 produced permanent 
impairment (Haller and Benowitz, 2000).  
 
2.3. Assessment Tools 
2.3.1. Analytical Quantification 
It has been reported that the type of alkaloid and the content of each alkaloid 
in dietary supplements vary from product to product (Gurley et al., 2000). Several 
analytical methods have been established to determine and quantify the ephedrine-
type alkaloids in Ephedra species and in dietary supplements containing Ephedra, 
including capillary electrophoresis (Liu et al., 1992; Flurer et al., 1995; Chinaka et 
al., 2000), chiral gas chromatography (Betz et al., 1997), gas chromatography with 
mass spectrometry (GC-MS) (Hansen, 2001), high performance liquid 
chromatography  (HPLC) with ultraviolet (UV) detection (Gurley et al., 1998; Sheu 
and Huang, 2001) and with mass spectrometry detection (LC-MS) (Gay et al., 2001) 




Among the analytical methods developed to date, HPLC methods are 
preferred because separation of all the six major bioactive components is achieved 
using HPLC (Sheu and Huang, 2000).  Improved HPLC methods are available 
including different extraction methods (Hurlbut et al., 1998; Ichikawa et al., 2003), 
types of column (Sheu and Huang, 2000), and mobile-phase compositions (Sheu and 
Huang, 2000; Dong et al., 2002).  
 
2.3.2. In Vitro Cytotoxicity 
In vitro cytotoxicity methods are important tools to enhance our understanding 
of hazardous effects caused by chemicals or bioactive components , which avoids 
using animals (Broadhead and Combes, 2001). In vitro cytotoxicity tests provide 
useful and necessary information in defining basal cytotoxicity, which is commonly 
used as a starting point in an integral assessment of potential in vivo toxicity of 
chemicals or active components in foods (Eisenbrand et al., 2002).  
The endpoints frequently used in cytotoxicity testing are based on the 
breakdown of the cellular permeability barrier, reduced mitochondrial function, 
changes in cell morphology, and changes in cell replication (Eisenbrand et al., 2002). 
Several methods have been developed for measurement of cell proliferation; counting 
cells that exclude a dye (trypan blue), measuring released 51Cr-labeled protein after 
cell lysis, measuring incorporation of radioactive nucleotides ([3H]thymidine or 
[125I]iododeoxyuridine) during cell proliferation, and measuring colorimetric changes 
of tetrazolium salts in active cells (Barile, 1994). Among these methods, the 




hazardous radio-active materials, and it is suitable for handling a large number of 
samples. (Lee et al., 2000)  
MTT (3-(4,5-dimetylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) is a 
tetrazolium salt that is reduced to yield a purple-colored water-insoluble formazan 
product (Altman, 1976). Since MTT is cleaved only by active mitochondria in living 
cells and not by dead cells or erythrocytes, MTT reduction is the most widely used 
method for measuring cell proliferation and viability (Mosmann, 1983; Hansen et al., 
1989). The formazan salt is produced in proportion to the active cell number, and 
accumulates within the cell since it is not membrane permeable. However when 
dimethyl sulfoxide (DMSO), isopropanol or other suitable solvent is added, formazan 
salt can be quantified calorimetrically. The MTT assay is simple and suitable for a 
wide variety of cell lines (Barile, 1994). However, the MTT assay requires 
monitoring as duration of MTT treatment, concentration of MTT used, and the 
number of test cells. These experimental conditions need to be taken into 
consideration when comparing inter-laboratory results (Lee et al., 2000). 
 
2.3.3. Biosensing Using Bioluminescent Reporter Bacteria 
Bioluminescent bacteria containing lux reporter fusions have been extensively 
studied due to their potential as a sensing element in biosensors however they can 
respond selectively to analytes and/or environmental stresses.  Their responses could 






Figure 2-2. Principle of biosensing using bioluminescent reporter bacteria 
(adapted from Belkin, 2003) 
 
Figure 2-2 summarizes the principle of bacterial biosensing. A molecular 
reporter such as lux and -gal is fused to specific gene promoter, which is known to 
be activated by the specific chemicals or stress conditions (Belkin, 2003).  Since 
bioluminescent bacteria containing lux reporter fusions are able to provide 
quantitative or semi-quantitative analytical information specific to analytes in a short 
period of time without additional processing steps, they have been widely used for 
monitoring of chemicals or hazardous substances in the environment instead of 




Belkin et al., 1996, 1997; Vollmer et al., 1997; Davidov et al., 2000; Rosen et al., 
2000).  
Figure 2-3 summarizes the mechanism of light emitting reaction controlled by 
each lux gene. The five structural genes encode luciferase (luxAB) and fatty acid 
reductase complex (luxCDE) catalyzing the biosynthesis of fatty aldehyde substrate. 
The bioluminescence reaction is a result of the oxidation of the fatty aldehyde and 
reduced flavin mononucleotide (FMNH2) catalyzed by luciferase (luxAB) (Meighen, 
1991). 
In the genetically engineered bioluminescent bacteria, the lux reporter genes 
controlling luciferase are placed under the control of a promoter that is activated by 
the presence of specific chemicals and/or cellular activity. When bacteria are exposed 
to hazardous chemicals or other environmental stresses, the genetic control 
mechanism turns on the synthesis of luciferase, which produces a visible blue-green 
light emission that is easy to monitor and quantify. The lux reporter genes have 
advantages compared to lacZ genes and other reporter genes used in bacterial systems 
because the activity can be monitored in real time without cell lysis (Rozen et al., 
2001). Moreover, if the five-gene luxCDABE reporter is used, the activity of the 
reporter may be assayed directly without any additional substrate since all the 














Figure 2-3.  Bacterial bioluminescence pathway 






Various bioluminescent strains have been constructed to enable screening for 
specific toxic mechanisms. However, it is impossible to cover all potential cellular 
stress factors with a single reporter gene. Therefore, a panel of genetically engineered 
strains should be used to increase their light production in response to a different type 
of stress such as oxidative stress (Belkin et al., 1996), DNA damage (Vollmer et al., 
1997; Davidov et al., 2000) and protein damage (Van Dyk et al., 1994) caused by the 
presence of organic chemical pollutants such as naphthalene, toluene and 
isopropylbenzene. Choi and Gu (2002) developed a biosensor kit using four 
recombinant bioluminescent E. coli strains. This biosensor enables one to detect 
toxicity of different chemicals on-site by using freeze-dried E. coli cells which show 
an increased bioluminescence under specific stressful conditions (e.g. DNA damage, 
protein damage, membrane damage, and oxidative stress) (Choi and Gu, 2002).  
The limitations of bioluminescent bacteria containing lux reporter fusions are 
that they may need a longer time to return to the baseline signal after use, and hence 
reversibility may be a problem. Also, the response tends to be slow relative to 
enzyme-based sensors since the substrate must first diffuse through the cell wall 
(D’Souza, 2001).  
Bioluminescent bacteria containing lux reporter fusions have been mainly 
used for environmental monitoring: they are also applied for food bacterial detection 
in food, screening for bioactive component in food industry and food research, quality 
control, and detection of naturally occurring hazardous components. Vansal and 




1-, 2- and 3-adrenergic receptors in Chinese hamster ovary (CHO) cells transfected 
with a 6 CRE-LUC plasmid by measuring the light production.  




CHAPTER 3: OBJECTIVES 
 
The objective of this study was to evaluate bioactivity of ephedrine-type 
alkaloids by measuring its cytotoxicity against animal cell lines and analyzing the 
stress responses of a panel of genetically engineered biosensing bacterial strains 
capable of producing real-time responses to specific cell damages. This bioassay 
integrating cytotoxicity assessment with real-time biosensing is a systematic approach 
to screening Ephedra bioactivity, and the knowledge obtained from the damage 
caused by active components of Ephedra on the living cells will help to establish in 
vitro assessment tool, and to identify the damage mechanism of ephedrine-type 
alkaloids. 
To accomplish these objectives, the experiments was divided into two parts; 
two cell lines, human neuroblastoma and rat myoblastoma, were used to detect and 
profile the cytotoxicity of major ephedrine-type alkaloids, ephedrine and 
pseudoephedrine, using a MTT cell proliferation assay. Secondly, six strains of 
bioluminescent E. coli were used to identify the stress fingerprints induced by the 







CHAPTER 4: MATERIALS AND METHODS 
 
4.1. Cytotoxicity Assessment Using MTT Cell Proliferation Assay 
4.1.1. Materials 
Ephedrine-type alkaloids, (1R, 2S)-(-)-ephedrine (99%) and (1S, 2S)-(+)-
pseudoephedrine (98%), were purchased from Aldrich (Allentown, PA). And the 
Minimum Essential Medium Alpha Medium and F-12 Nutrient Mixture (HAM) were 
from Invitrogen life technologies (Carlsbad, CA).  Dulbecco’s Modified Eagle’s 
Medium (DMEM), MTT cell proliferation assay kit and other reagents for cell 
cultures were from the American Type Culture Collection (ATCC, Manassas, VA). 
 
4.1.2. Cell Cultures 
Human neuroblastoma cell line (SH-SY5Y) (ATCC #CRL-2266) and rat 
myoblast cell line (H9c2 (2-1)) (ATCC #CRL-1446) were purchased from ATCC. 
SH-SY5Y and H9c2 (2-1) were routinely maintained in 1:1 Minimum Essential 
Medium/F-12 Nutrient Mixture (HAM) and in Dulbecco’s Modified Eagle’s Medium 
(DMEM) respectively. Both culture media are supplemented with 10% fetal bovine 
serum. Cells were incubated in a humidified atmosphere of 5% CO2 at 37°C.  
 
4.1.3. MTT Assays 
MTT cell proliferation assay kit was used to determine the cytotoxicity of 




maintenance cultures in the exponential phase, stained with trypan blue and counted 
by a hemocytometer. Cell suspensions (200 l) were dispensed into 96-well flat-
bottomed tissue culture plates at concentrations of 2 x 105 cells/ml for SH-SY5Y and 
3 x 104 cells/ml for H9c2 (2-1). After a recovery period (72-hour for SH-SY5Y and 
48-hour for H9c2 (2-1)), the media were removed from the wells with a hypodermic 
needle attached to a suction line, and then various concentrations of ephedrine-type 
alkaloids ranging from 0.1 to 1.0 mg/ml diluted in 200 l growth media were added 
to each well. Control wells received only 200 l growth media. Plates were incubated 
at 37°C in 5% CO2 for 72 hours. The media was then aspirated from the wells with a 
hypodermic needle attached to a suction line, and 100 l of fresh media added. Ten l 
of MTT Reagent was added to each well, and the plates were incubated for 4 hours. 
One hundred l of Detergent Reagent (sodium dodecyl sulfate) was added to each 
well, and the plates left at room temperature in the dark overnight. The absorbance of 
each well was read by the Opsys MR Microplate Reader (Thermo Labsystems, 
Chantilly, VA) at 570 nm with 690 nm as the reference wavelength.  
 
4.1.4. Data Analysis 
The relative viability of the treated cells as compared to the control cells was 
expressed as the % cytoviability, using the following formula: 
% cytoviability = [A570 of treated cells]  100% / [A570 of control cells]. 
The IC50 (median inhibition concentration) was determined by nonlinear 
regression analysis of the corresponding dose response curve utilizing the analytical 




The results were presented as the mean ± standard error of the mean (S.E.M.) of four 
experiments, and Student’s t-test was used to assess the significance of the data.  
 
4.2. Real-Time Biosensing Using Bioluminescent E. coli Strains  
4.2.1. Bioluminescent E. coli strains 
Six bioluminescent E. coli strains obtained from DuPont Genetics Lab (DuPont 
Company, Wilmington, DE) was used in this study. Each strain contained different 
selected stress-responsive promoter fused to the Photorhabdus luminescence 
luxCDABE reporter. The panel strains were chosen to represent a range of stress 
responses to result in different patterns of induced gene expression. Each strain 
responds respectively to oxidative damage, internal acidification, DNA damage, 
protein damage, “super-stationary phase” and sigma S stress (Table 4-1) (Van Dyk, 
1998). There are two sets of the stress-responsive E. coli strains, and one set 
introduces an outer membrane mutation, tolC, which enables highly sensitive 
detection of a variety of organic molecules because their ability to pump out 
undesired molecules is limited (Davidov et al., 2000). In this experiment, the set of 
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The E. coli strains were maintained in a 70% glycerol suspension at -78°C. 
Prior to the assay, the stock cultures were transferred to 250 ml flasks with 50 ml 
sterilized Luria Bertani (LB) medium and incubated for 12 hours at 37°C on a model 
1575 orbital shaking incubator (VWR Scientific, Cornelius, OR) at 300 rpm. To 
ensure stability of the plasmids containing lux fusion genes, ampicillin (100 µg/ml) 
was added in the growth media of all the strains except for strains DPD2222 and 
DPD2234, which have the lux gene fusion in their chromosomes. 
 
4.2.2. E. coli stress fingerprinting 
Cultures of each E. coli strain were diluted with sterile distilled water at a 
ratio of 1:10. Nine hundred µl of culture solution was placed in a transparent glass 
cuvette. Luminescence from E. coli of each cuvette was measured by a TD-20e 
luminometer (Turner Designs, Sunnyvale, CA) and the luminescence values were 
presented as instrument’s arbitrary relative light unit (RLU).  The RLU value was 
recorded again after 100 µl of ephedrine-type alkaloids. The difference and ratio of 
the two RLU values (“before RLU” and “after RLU”) were both calculated to 
indicate the stress responses from the bioluminescent E. coli strains.  
 
RLU = “after RLU” – “before RLU” 
RLU ratio = “after RLU”/”before RLU” 
 
If the RLU rations are greater than 1.0 (“lights-on”), it indicates that the lux 




are less than 1.0 (“lights-off”), it suggests a dampening of bioluminescent E. coli 
strains in the presence of ephedrine-type alkaloids.  
 
4.2.3. Data Analysis 
 Data are presented as mean ± the standard errors of the mean (S. E. M.). 
Statistical analysis was performed using either Student’s t-test or analysis of variance 
(ANOVA) utilizing the analytical software package GraphPad Prism Version 4 
(GraphPad Software, San Diego, CA). For ANOVA, pairwise comparisons between 












CHAPTER 5:  RESULTS AND DISCUSSION 
 
5.1. Cytotoxicity Assessment Using MTT Cell Proliferation Assay 
5.1.1. Effects of Ephedrine and Pseudoephedrine on Cytoviability 
 Cytotoxicity against two different cell lines was evaluated by determining the 
IC50 values of (-)-ephedrine and (+)-pseudoephedrine. The cytoviability of SH-SY5Y 
and H9c2 (2-1) cells in the presence of ephedrine-type alkaloids is given in Figure 5-
1. In each case, the percentage of viable cells decreased significantly in a dose-
dependent manner.  
For each replicate, the concentration resulting in 50% inhibition (IC50) was 
determined using nonlinear regression analysis. Figure 5-2 shows an example dose-
response curve obtained from MTT cytotoxicity assessment of (-)-ephedrine using 
SH-SY5Y. Percentage cytoviability ([absorbance of test cells/absorbance of control 
wells]  100) was plotted against the log concentration of (-)-ephedrine.  
The IC50 values for (-)-ephedrine and (+)-pseudoephedrine on SH-SY5Y and 
H9c2 (2-1) are presented in Table 5.1. Both (-)-ephedrine and (+)-pseudoephedrine 
were inhibitory to cell growth of SH-SY5Y and H9c2 (2-1). For SH-SY5Y, the IC50 
value of (-)-ephedrine was 0.619 ± 0.004 mg/ml and (+)-pseudoephedrine was 0.605 
± 0.011 mg/ml.  These values were not significantly different. For H9c2 (2-1), the 
IC50 value of (-)-ephedrine was 0.617 ± 0.005 mg/ml and (+)-pseudoephedrine was 
0.666 ± 0.012 mg/ml.  A Student’s t-test showed that the IC50 value of (-)-ephedrine 







b) H9c2 (2-1) 
 
 
Figure 5-1.  Effects of ephedrine-type alkaloids on SH-SY5Y and H9c2 (2-1) cell 









Figure 5-2. Sample dose-response curve. Percentage cytoviability ([absorbance of 














results indicate that H9c2 (2-1) could differentiate the cytotoxicity of (-)-ephedrine 
and (+)-pseudoephedrine while SH-SY5Y showed similar sensitivity to both 
ephedrine-type alkaloids. Figure 5-3 shows morphological changes of H9c2 (2-1) cell 
line when it was treated with (-)-ephedrine for 72 hours. As the concentration of (-)-
ephedrine increases, swelling of the cells became prominent and vacuolar 
degeneration was observed microscopically. 
 
5.1.2. Effects of Combined Treatments by Ephedrine and Pseudoephedrine 
The cumulative effects of (-)-ephedrine and (+)-pseudoephedrine on the 
cytoviability of SH-SY5Y and H9c2 (2-1) cells were illustrated in Figure 5-4. At low 
concentrations of (-)-ephedrine (0.2 mg/ml) and (+)-pseudoephedrine (0.2 mg/ml), the 
cytoviability of SH-SY5Y cells were suppressed 11 and 12%, respectively. The 
combined treatment suppressed cytoviability 18%, slightly lowering the 23% 
predicted by the sum of the individual suppression. Other combination of (-)-
ephedrine (0.4 mg/ml) and (+)-pseudoephedrine (0.2 mg/ml) suppressed the 
cytoviability to the extent predicted by the individual effects while the combination of 
(-)-ephedrine (0.2 mg/ml) and (+)-pseudoephedrine (0.4 mg/ml) suppressed the 
cytoviability to the larger extent than additive effect. For H9c2 (2-1), on the other 
hand, all the combinations of (-)-ephedrine and (+)-pseudoephedrine showed lesser 




Table 5-1. The IC50 values of (-)-ephedrine and (+)-pseudoephedrine for two cell 
lines. 
                  
  IC50 (mg/ml) 
 Cell Lines   ephedrine   pseudoephedrine 
         
SH-SY5Y   0.619 ± 0.004a  0.605 ± 0.011a 
         
         
H9c2 (2-1)   0.617 ± 0.005a  0.666 ± 0.012b 
                  
         
Each value is the mean ± S.E.M., n=4.       
IC50: concentration of test sample to inhibit cytoviability by 50%   




































Figure 5-3. H9c2 (2-1) cells treated with (-)-ephedrine. 200 magnifications. A: 
control; B, C, and D: cells treated with (-)-ephedrine 0.2 mg/ml, 0.4 mg/ml, and 0.6 
















































Figure 5-4. Cumulative effects of two ephedrine-type alkaloids on the 
cytoviability of SH-SY5Y and H92c (2-1). Shown are mean ± S. E. M. for n=6.  






 Among the adverse events potentially associated with dietary supplements 
containing ephedrine-type alkaloids reported to FDA from 1997 through 1999, 
approximately 60% of the total reports were characterized as clinically serious such 
as deaths, cardiovascular events, and serious nervous system effects. Serious nervous 
system effects including seizures, psychosis and depression accounted for 16% of the 
total adverse events (FDA, 2000). Lee et al. (2000) assayed the cytotoxicity of pure 
ephedrine and extracts of Ephedra using a mouse neuroblastoma cell line (Neuro-2a) 
and reported that Neuro-2a was more sensitive to Ephedra extracts compared to other 
cell lines including human hepatoblastoma (HepG2).  In this study, a human 
neuroblastoma cell line SH-SY5Y, which is frequently used in the assessments of 
cytotoxicity or protective effects for other chemicals (Slaughter et al., 2002; Legros et 
al., 2004; Miglio et al., 2004), was employed instead of mouse neuroblastoma cell 
line, to investigate whether it would show similar sensitivity to ephedrine-type 
alkaloids. 
 Serious cardiovascular events that included myocardial infraction (MI), 
unstable angina, dysrhythmias and transient ischemic attacks, accounted for 31% of 
reported adverse events (FDA, 2000). Therefore, rat myocardium cell line (H9c2 (2-
1)) was used in this MTT cytotoxicity assessment in addition to SH-SY5Y. The H9c2 
(2-1) cell line is a permanent cell line derived from rat heart tissue, that shows 
morphological characteristics similar to those of immature embryonic cardiocytes and 




found in adult rat cardiac myocytes (Hescheler et al., 1991). Also, it has been 
reported that H9c2 (2-1) expresses both 1- and 2-adrenergic receptors on which 
ephedrine acts (Dangel et al., 1996). Therefore, H9c2 (2-1) cell line was expected to 
be a useful model for cytotoxicity assessment of ephedrine-type alkaloids.  
With regard to the cytotoxicity of (-)-ephedrine, the IC50 values achieved from 
the current study (0.615 ~ 0.616 mg/ml) were close to the results previously reported 
(Lee et al., 2000). However, Lee et al. also reported that the cytotoxicity of (-)-
ephedrine was significantly higher than that of (+)-pseudoephedrine when they 
determined the % cytoviability of equimolar concentrations (3.0 mM = approximately 
0.50 mg/ml) of (-)-ephedrine and (+)-pseudoephedrine for HepG2 cell line (30.8% for 
(-)-ephedrine and 89.4% for (+)-pseudoephedrine). In the current study, the % 
cytoviability of 0.50 mg/ml of (-)-ephedrine and (+)-pseudoephedrine was 83.7% and 
76.5% for SH-SY5Y and 91.4% and 86.1% for H9c2 (2-1) respectively, and 
Student’s t-test showed no significant difference in either cell line at this level of 
concentration. The same can be said for the IC50 values. There was no significant 
difference between (-)-ephedrine and (+)-pseudoephedrine for SH-SY5Y. Although (-
)-ephedrine is considered to be more potent and toxic than (+)-pseudoephedrine 
clinically (Tang, 1996), it is possible that the sensitivity to (-)-ephedrine and (+)-
pseudoephedrine is different from cell line to cell line, and it may not be necessarily 
appropriate to suggest that (-)-ephedrine is more cytotoxic than (+)-pseudoephedrine. 
For H9c2 (2-1), (-)-ephedrine was proved to be more cytotoxic but the difference was 




Although there is a little data on blood and tissue levels of (-)-ephedrine and 
other ephedrine-type alkaloids in humans, Haller et al. (2002) reported that maximum 
plasma concentrations were 63.5 ng/ml for ephedrine and 24.1 ng/ml for 
pseudoephedrine 2.4 hours after the ingestion of dietary supplements containing 
ephedrine-type alkaloids (17.3 mg ephedrine, 5.3 mg pseudoephedrine and 
insignificant amounts of the other alkaloids on an average).  Other studies also 
showed that the therapeutic plasma levels of ephedrine in humans following ingestion 
of ephedrine in the form Ephedra sinica capsules (19 mg ephedrine), an ephedrine 
tablet (20 mg ephedrine), or an ephedrine solution (22 mg) are 81 ng/ml, 74 ng/ml, 
and 79 ng/ml respectively (Vansal and Feller, 1999). The IC50 values achieved from 
the present study were 0.605 ~ 0.666 mg/ml, which were several orders of magnitude 
higher than the therapeutic plasma levels. Therefore, it is difficult to directly associate 
the in vitro cytotoxic effects with the actual adverse responses of human.  
Ephedrine is both a direct and indirect adrenergic agonist (Abourashed et al., 
2003). That is, ephedrine activates adrenergic receptors both by direct agonist activity 
as well as by releasing norepinephrine via carrier-mediated exchange mechanism. 
Ephedrine possesses two asymmetrical carbon atoms and exists as four isomers. 
Among these four ephedrine isomers, (-)-ephedrine and (+)- pseudoephedrine are 
naturally contained in some of the Ephedra species (Vansal and Feller, 1999). Vansal 
and Feller (1999) reported (-)-ephedrine was the most potent of the four ephedrine 
isomers on human -adrenergic receptors expressed in Chinese hamster ovary cells. 
However, Rothman et al. (2003) reported that ephedrine-type alkaloids showed no 




pharmacological actions of ephedrine and its derivatives resulted primarily from 
release of norepinephrine rather than direct activation of adrenergic receptors. 
Although the cell lines employed in this study are reported to express several 
subtypes of the adrenergic receptors (Dangel et al., 1996), it is not known if their 
response resulted from the direct effects on a specific adrenergic receptor or from 
indirect effects. However, the MTT assay using these cell lines may serve as an 
efficient model to detect general cytotoxicity of compounds included in dietary 
supplements. 
 Although little is known about the cytotoxicity of other ephedrine-type 
alkaloids and compounds in Ephedra, norpseudoephedrine is known to be more 
potent than (-)-ephedrine with regard to CNS stimulation (Kalix, 1991). Moreover, 
the presence of toxins in Ephedra other than (-)-ephedrine is suggested since IC50 
values of Ephedra extracts normalized by their (-)-ephedrine contents were 
significantly lower than pure (-)-ephedrine (Lee et al., 2000). Dietary supplements 
containing ephedrine-type alkaloids often include other agents including stimulants, 
diuretics and cathartics (CANTOX, 2000).   The synergistic interaction between 
ephedrine-type alkaloids and caffeine is well known (Haller et al., 2004). Therefore, 
it may also be useful to evaluate the interaction between ephedrine-type alkaloids and 
other functional compounds using this MTT cytotoxicity assessment. 
 In response to the FDA’s decision to ban the sales of Ephedra-containing 
dietary supplements, manufacturers and companies have developed new “Ephedra-
free” dietary supplements (Marcus and Grollman, 2003). One of the most popular 




component “synephrine” is an ephedrine-type alkaloid and the combination of 
synephrine and caffeine has the similar potential to induce cardiac arrhythmias, 
hypertension, heart attacks, and strokes as the combination of Ephedra and caffeine 
(Marcus and Grollman, 2003). The association of dietary supplements containing 
bitter oranges with myocardial infarction has been reported (Nykamp et al., 2004). 
Therefore, there is a concern that the misuse of “emerging” dietary supplements 
containing botanical substances might cause other health problems. The MTT 
cytotoxicity assay used in the present study could serve as a useful assessment tool to 
analyze the cytotoxic pattern of other botanical substances contained in dietary 
supplements and to predict potential adverse effects. 
 
5.2. Real-Time Biosensing Using Bioluminescent E. coli Strains  
The RLU ratio of the E. coli strains exposed to (-)-ephedrine and (+)-
pseudoephedrine at differing concentrations (0.03 mg/ml to 0.06mg/ml) is 
summarized in Figures 5-5 - 5-8. All strains showed increased bioluminescence in 
response to the stress caused by (-)-ephedrine and (+)-pseudoephedrine at the 
concentrations as low as 0.03 mg/ml. This concentration was much lower than the 
ID50 (0.605 ~ 0.666 mg/ml) obtained from the cytotoxicity assessment using human 
and rat cell lines. 
The RLU ratio of a panel of bioluminescent E. coli strains exposed to (-)-ephedrine 
and (+)-pseudoephedrine at a concentration of 0.3 mg/ml is presented in Figure 5-9. 
Both (-)-ephedrine and (+)-pseudoephedrine decreased the RLU ratios and was toxic 




DPD2240) for (-)-ephedrine were less than 1.0 (“Lights-off” response) which could 
be attributed to inhibition of cellular metabolism required for production of energy or 
reduction power (Chatterjee and Meighen, 1993), and the RLU ratios were 
significantly lower than those of (+)-pseudoephedrine, whereas there was no 
significant difference in strains DPD2222 and DPD2234. These results indicate that 
this biosensing panel was sensitive to the bioactive effects caused by ephedrine-type 
alkaloids and it distinguished (-)-ephedrine and (+)-pseudoephedrine. The strains 
DPD2222 and DPD2234 showed less intense response to (-)-ephedrine compared to 
other 4 strains. A possible reason for this is that the host strain of DPD2222 and 
DPD2234 is MM28, which is different from the parental strain of other 4 strains 
(GC4468). Moreover, DPD2222 and DPD2234 have their lux-fusions in their 
chromosome while the other strains have plasmids containing lux-fusions. These 
might affect the sensitivity to detect the toxicity of ephedrine-type alkaloids in short 
time.  
At a concentration of 0.03 mg/ml, (-)-ephedrine induced increased 
bioluminescence in DPD2222, DPD2232 and DPD2234. In contrast, (+)-
pseudoephedrine induced bioluminescence in DPD2222, DPD2232 and DPD2233. 
Strains DPD2238 and DPD2240 showed no significant response to either (-)-
ephedrine or (+)-pseudoephedrine. Also, RLU ratios of (-)-ephedrine and (+)-
pseudoephedrine were not significantly different in all strains. 
 At a concentration of 0.04 mg/ml, (-)-ephedrine induced increased 
bioluminescence in DPD2232, DPD2233 and DPD2234, and the RLU ratio of 




pseudoephedrine only increased the RLU ratio in strain DPD2232. Strains DPD2222, 
DPD2238 and DPD2240 showed no significant responses either to (-)-ephedrine or 
(+)-pseudoephedrine.  
 At the concentration of 0.05 mg/ml, (-)-ephedrine induced increased 
bioluminescence in DPD2222, DPD2232 and DPD2233 compared to the control 
although they were not significantly different from those of (+)-pseudoephedrine. On 
the other hand, (+)-pseudoephedrine also increased the RLU ratio of strains DPD2222 
and DPD2232. Strains DPD2234, DPD2238 and DPD2240 showed no significant 
responses either to (-)-ephedrine or (+)-pseudoephedrine.  
 At a concentration of 0.06 mg/ml, (-)-ephedrine induced bioluminescence in 
DPD2222, DPD2232, DPD2233 and DPD2240 compared to the control although they 
were not significantly different from those of (+)-pseudoephedrine. (+)-
Pseudoephedrine also increased the RLU ratio in strains DPD2222 and DPD2232. 
Strains DPD2234 and DPD2238 showed no significant responses either to (-)-
ephedrine or (+)-pseudoephedrine.  
 Strain DPD2233 showed increased response to (-)-ephedrine in the 
concentration range of 0.04 mg/ml ~ 0.06 mg/ml. Strain DPD2233 is constructed to 
contain the plasmid in which the E. coli yciG promoter is fused to luxCDABE genes. 
As expression of yciG gene is under control of the stationary phase sigma factor s, 
the yciG-lux fusion is expected to report on the activation of the s-dependent stress 
response (Van Dyk, 1998).  
 In the present study, (-)-ephedrine slightly increased the bioluminescence of 




no significant increase of RLU ratio when exposed to (+)-pseudoephedrine.  
Escherichia coli strain DPD2234 contains chromosomal insertion of a grpE promoter 
fused to the P. luminescens luxCDABE. Since grpE gene is in the heat shock regulon 
controlled by 32, the grpE-lux fusion responds to stresses that induce this protein-
damage responsive regulon (Van Dyk, 1998), and it is also known to respond to a 
variety of stresses and chemicals (Van Dyk et al., 1995).  Increased RLU ratio of the 
strain DPD2234 indicated the induction of the general stress-response by (-)-
ephedrine.   
Both (-)-ephedrine and (+)-pseudoephedrine appeared to increase the RLU 
ratio of strain DPD2222, which is designed to respond to DNA damage through SOS 
regulatory circuit. The increased RLU ratio of DPD2222 indicated the possibility that 
DNA damage-sensing SOS response was induced by both (-)-ephedrine and (+)-
pseudoephedrine. Strain DPD2222 is the one that contains chromosomal insertion of 
E. coli recA promoter fused to the P. luminescens luxCDABE. When DNA damage is 
present, a resultant single stranded DNA acts as a signal for induction of the SOS 
response (Daunert et al., 2000). According to the studies on the genotoxicity of 
ephedrine and Ephedra extract, both in vitro and in vivo, ephedrine sulfate had no 
genotoxicity in three strains of Salmonella typhimurium (TA97, TA98, TA100 and 
TA1535), nor in cultured Chinese hamster ovary (CHO) cells (NTP, 1986). Hillard et 
al. (1998) reported that ephedrine sulfate was negative in two chromosome aberration 
tests using CHO cells. These studies demonstrated that ephedrine and Ephedra are not 
genotoxic. Although SOS activation in itself does not imply genotoxicity, the two 




thus needed to determine whether mechanisms other than DNA damages are involved 
in the stress response obtained in the present study, or ephedrine-type alkaloids cause 
DNA damage but not mutation. 
 Strain DPD2238 showed no significant increase of RLU ratio when exposed 
to either (-)-ephedrine or (+)-pseudoephedrine in different concentrations. The strain 
DPD2238 is constructed to contain the plasmid in which the E. coli katG (catalase) 
promoter is fused to luxCDABE genes. An E. coli strain harboring this plasmid is 
known to exhibit low basal levels of luminescence, which increased up to 1,000-fold 
in the presence of oxidative stress such as hydrogen peroxide, organic peroxides, 
alcohols and cigarette smoke (Belkin et al., 1996). Kang et al. (1998) reported that 
ephedrine exerted mild antioxidant activity in vitro. The result from the present study 
that oxidative stress response was absent supports their observations.  If direct 
correlations could be established between antioxidant activity and oxidative stress 
response, strain DPD2238 could be used as a tool to assay antioxidant property of 
ephedrine-type alkaloids.  
Strain DPD2232 is constructed to contain the plasmid in which the E. coli 
o513 promoter is fused to luxCDABE genes. Although the regulation of o513 has not 
been well characterized, it was reported that expression of a lux fusion to an open 
reading frame o513 is highly induced as the culture ages, suggesting that stationary 
phase induces the expression of o513; however such expression is not controlled by 
s (Van Dyk, 1998). Van Dyk (1998) also observed that o513-lux fusion did not yield 
increased bioluminescence to the wide range of chemicals (e.g., hydrogen peroxide, 




ratio of less than 1.0 (“lights off”). Therefore, Van Dyk (1998) proposed to use the 
strain containing o513-lux fusion as a general indicator of toxicity. Interestingly, both 
(-)-ephedrine and (+)-pseudoephedrine significantly induced bioluminescence of the 
o513-lux fusion strain (DPD2232) compared to the control, and the “lights off” 
response was only observed for (-)-ephedrine at the high concentration of 0.3 mg/ml. 
This result suggests the possibility that o513 promoter is activated in response to the 









Figure 5-5. RLU ratio obtained from six E. coli strains exposed to 0.03 mg/ml of 











Figure 5-6. RLU ratio obtained from six E. coli strains exposed to 0.04 mg/ml of 
(-)-ephedrine and (+)-pseudoephedrine. Shown are mean ± S. E. M. for n=3. a p< 














Figure 5-7. RLU ratio obtained from six E. coli strains exposed to 0.05 mg/ml of 
(-)-ephedrine and (+)-pseudoephedrine. Shown are mean ± S. E. M. for n=3. a p< 











Figure 5-8. RLU ratio obtained from six E. coli strains exposed to 0.06 mg/ml of 
(-)-ephedrine and (+)-pseudoephedrine. Shown are mean ± S. E. M. for n=3. a p< 















Figure 5-9. RLU ratio obtained from six E. coli strains exposed to 0.3 mg/ml of (-




CHAPTER 6:  CONCLUSIONS 
 
In the present study, the bioactivity of two major ephedrine-type alkaloids 
were evaluated by measuring its cytotoxicity against the cell lines and analyzing the 
stress response of a panel of genetically engineered biosensing E. coli strains capable 
of producing real-time responses to specific cell damages.  
The two ephedrine-type alkaloids, (-)-ephedrine and (+)-pseudoephedrine, 
showed cytotoxicity to the human neuroblastoma SH-SY5Y and rat myoblastoma 
H9c2 (2-1) cell lines. SH-SY5Y cell lines showed similar sensitivity to (-)-ephedrine 
and (+)-pseudoephedrine while H9c2 (2-1) cell line was able to differentiate the 
cytotoxicity of (-)-ephedrine and (+)-pseudoephedrine. MTT assay using established 
cell lines could provide information on general information on cytotoxicity of 
ephedrine-type alkaloids, but a variety of cell lines should be used to assess 
organ/tissue toxicity.  
 Biosensing using a panel of bioluminescent E. coli strains was highly sensitive 
to ephedrine-type alkaloids and could produce a rapid response at the concentration as 
low as 0.03 mg/ml. Moreover, these E. coli strains distinguished the toxicity of (-)-
ephedrine and (+)-pseudoephedrine; the bioluminescence from the E. coli strains was 
significantly suppressed by (-)-ephedrine compared to (+)-pseudoephedrine at the 
high concentration 0.3 mg/ml.  At the lower concentrations, (-)-ephedrine generally 
induced higher bioluminescence than (+)-pseudoephedrine did throughout the 




fingerprinting pattern of ephedrine-type alkaloids, this biosensing panel has a 
potential to be a very effective clue for clarifying the toxicity mechanism of 
ephedrine-type alkaloids.  However, this biosensing panel did not give clear dose-
dependent response in the range of concentrations used in the present study. In order 
to obtain quantitative information, it might be needed to assess the stress response 







Table A-1. RLU ratio obtained from six E. coli strains exposed to 0.03 mg/ml of (-)-
ephedrine, (+)-pseudoephedrine or mixture of (-)-ephedrine and (+)-pseudoephedrine 
in different concentrations. 
 
 
                          
 RLU Ratio 
Strain ephedrine   pseudoephedrine   e + p*   
DPD2222 1.31 ± 0.01  1.28 ± 0.02  1.18 ± 0.02 
a 
             
DPD2232 1.32 ± 0.05  1.31 ± 0.02  1.20 ± 0.03  
             
DPD2233 1.29 ± 0.06  1.33 ± 0.03  1.31 ± 0.02  
             
DPD2234 1.36 ± 0.01  1.27 ± 0.03  1.31 ± 0.07  
             
DPD2238 1.26 ± 0.04  1.26 ± 0.02  1.29 ± 0.01  
             
DPD2240 1.24 ± 0.00  1.34 ± 0.06  1.37 ± 0.06  
                          
             
* e+p: 0.015 mg/ml (-)-ephedrine + 0.015 mg/ml (+)-pseudoephedrine.  




Table A-2. RLU ratio obtained from six E. coli strains exposed to 0.04 mg/ml of (-)-
ephedrine, (+)-pseudoephedrine or mixture of (-)-ephedrine and (+)-pseudoephedrine 
in different concentrations. 
 
 
                          
 RLU Ratio 
Strain ephedrine   pseudoephedrine   e + p*   
DPD2222 1.35 ± 0.11  1.24 ± 0.01  1.33 ± 0.04  
             
DPD2232 1.30 ± 0.02  1.30 ± 0.01  1.27 ± 0.02  
             
DPD2233 1.48 ± 0.04  1.20 ± 0.02 a 1.40 ± 0.05  
             
DPD2234 1.39 ± 0.04  1.24 ± 0.02  1.32 ± 0.06  
             
DPD2238 1.26 ± 0.06  1.24 ± 0.01  1.23 ± 0.00  
             
DPD2240 1.37 ± 0.11  1.24 ± 0.01  1.35 ± 0.01  
                          
             
* e+p: 0.02 mg/ml (-)-ephedrine + 0.02 mg/ml (+)-pseudoephedrine.  




Table A-3. RLU ratio obtained from six E. coli strains exposed to 0.05 mg/ml (-)-
ephedrine, (+)-pseudoephedrine or mixture of (-)-ephedrine and (+)-pseudoephedrine 




                          
 RLU Ratio 
Strain ephedrine   pseudoephedrine   e + p*   
DPD2222 1.30 ± 0.05  1.27 ± 0.01  1.30 ± 0.01  
             
DPD2232 1.32 ± 0.02  1.33 ± 0.01  1.25 ± 0.04  
             
DPD2233 1.45 ± 0.10  1.22 ± 0.02  1.32 ± 0.01  
             
DPD2234 1.29 ± 0.06  1.24 ± 0.01  1.30 ± 0.01  
             
DPD2238 1.03 ± 0.13  1.22 ± 0.02  1.35 ± 0.05  
             
DPD2240 1.56 ± 0.20  1.22 ± 0.01  1.45 ± 0.07  
                          
             
* e+p: 0.025 mg/ml (-)-ephedrine + 0.025 mg/ml (+)-pseudoephedrine.  





Table A-4. RLU ratio obtained from six E. coli strains exposed to 0.06 mg/ml (-)-
ephedrine, (+)-pseudoephedrine or mixture of (-)-ephedrine and (+)-pseudoephedrine 




                          
 RLU Ratio 
Strain ephedrine   pseudoephedrine   e + p   
DPD2222 1.23 ± 0.02 a 1.30 ± 0.01 b 1.29 ± 0.01 ab 
             
DPD2232 1.36 ± 0.07  1.36 ± 0.05  1.15 ± 0.01  
             
DPD2233 1.51 ± 0.02 a 1.30 ± 0.04 ab 1.24 ± 0.04 b 
             
DPD2234 1.32 ± 0.06  1.32 ± 0.03  1.20 ± 0.01  
             
DPD2238 1.05 ± 0.26  1.30 ± 0.02  1.17 ± 0.02  
             
DPD2240 1.38 ± 0.04  1.26 ± 0.01  1.32 ± 0.03  
                          
             
* e+p: 0.03 mg/ml (-)-ephedrine + 0.03 mg/ml (+)-pseudoephedrine.  
Each value is mean ± S. E. M., n=3. 
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